Assessment of prognosis by established prognosis scores and physicians' judgement in mRCC patients: an analysis of the STAR-TOR registry.

Boegemann, Martin; Goebell, Peter Jürgen; Woike, Michael; Buncke, Johanna; Schlack, Katrin; Schrader, Andres Jan

Boegemann, Martin; Goebell, Peter Jürgen; Woike, Michael; Buncke, Johanna; Schlack, Katrin; Schrader, Andres Jan.

Afiliação

Boegemann M; Department of Urology, Muenster University Medical Center, Albert-Schweitzer-Campus 1 GB A1, Muenster, Germany.
Goebell PJ; Department of Urology, Erlangen University Medical Center, Erlangen, Germany.
Woike M; Pfizer Pharma GmbH, Linkstrasse 10, Berlin, Germany.
Buncke J; Pfizer Pharma GmbH, Linkstrasse 10, Berlin, Germany.
Schlack K; Department of Urology, Muenster University Medical Center, Albert-Schweitzer-Campus 1 GB A1, Muenster, Germany.
Schrader AJ; Department of Urology, Muenster University Medical Center, Albert-Schweitzer-Campus 1 GB A1, Muenster, Germany.

Transl Androl Urol ; 10(10): 4062-4074, 2021 Oct.

Article em En | MEDLINE | ID: mdl-34804848

Palavras-chave

Renal cell carcinoma (RCC); Temsirolimus; mTOR inhibitor; prognosis; subjective assessment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Transl Androl Urol Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google